UPDATE 1-Momenta sees longer US review for generic Lovenox

(Reuters) - Momenta, whose shares fell 13.9 percent in pre-market
trading, said it originally expected the U.S. Food and Drug
Administration review to take 18 to 24 months from when it
filed the application in August 2005.




In a filing, the company said the review will "likely
extend" beyond its prior view "due to a change in the projected
timing of certain activities required for the completion of the
FDA's review."


Read more at Reuters.com Government Filings News